Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Expert Updates in Gram Negative Resistance

Thursday, June 11, 2020, 12:00 PM - 1:00 PM CT
  -  Register to attend June 11

 

 

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities
 

Activity Description

As the world shifts focus to mortality reduction during the COVID-19 pandemic, clinicians may find themselves strained when managing serious bacterial infections. Gram-negative infections often appear in the most critically ill patients, and with a potential for considerable strain on ICU beds, continuing education may significantly impact outcomes. As novel antibiotics are approved, appropriate and conservative use may be essential to maintain their efficacy.

Clinical and infectious diseases professionals must have the most up to date information about the spectrum of antimicrobial activity, dosing, adverse effects, and place in therapy to guide appropriate use of new agents and information about emerging therapies on the horizon. Importantly, an analysis of which agent is approved for what indication, the gram-negative coverage profile, unique patient considerations – such as renal or hepatic impairment – and overall dosing and monitoring are critical in managing new treatments. In this activity, subject matter experts will discuss the knowledge and practice surrounding the use of antibiotics for gram-negative infections.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

  • Outline the most recent epidemiological patterns in gram-negative bacterial resistance and the burden on clinical practice.
  • Discuss current and emerging novel antimicrobials by gram-negative coverage, indication, dosing, and side effects.
  • Identify antimicrobial stewardship principles for novel antimicrobials including place in practice, empirical use, susceptibility testing, and formulary considerations.

Faculty

Kimberly C. Claeys, PharmD, BCPS
Assistant Professor Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Keith S. Kaye, MD, MPH
Professor of Internal Medicine
Director of Research, Division of Infectious Diseases
University of Michigan Medical School
Ann Arbor, Michigan

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-278-L01-P has been assigned to this live knowledge-based activity (initial release date 6-11-2020). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

It is the policy of ProCE, Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. Faculty conflict of interest will be announced prior to the start of the CE activity.

Funding

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

    

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.